Efficacy and Safety of Once-Daily Vilanterol/Fluticasone Furoate MDI in Persistent Asthma: Phase 3 OD-INHALE study
Conclusion: Once daily VI/FF pMDI was non-inferior to twice daily FOR/FP pMDI in patients with persistent asthma.PMID:38488853 | DOI:10.1080/02770903.2024.2330485 (Source: Journal of Asthma)
Source: Journal of Asthma - March 15, 2024 Category: Respiratory Medicine Authors: Avdhesh Kumar Manish Kumar Jain Vijaykumar Bhagwan Barge Raghumanda Sunil Kumar Neeraj Gupta Harendra Yadav Amitava Pal Vivek Eknath Redkar Asish Mondal Rahul Kumar Rathore Pavankumar Daultani Ashok Jaiswal Ravi T Mehta Source Type: research
Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study – few concerns
This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it ... (Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - March 15, 2024 Category: Respiratory Medicine Authors: Divya Balan, Manish R Shetty and Manu K Mohan Tags: Matters Arising Source Type: research
ERS/EBMT clinical practice guideline on treatment of pulmonary chronic graft- < em > versus < /em > -host disease in adults
Eur Respir J. 2024 Mar 14:2301727. doi: 10.1183/13993003.01727-2023. Online ahead of print.ABSTRACTChronic graft-versus-host disease (cGvHD) is a common complication after allogeneic haematopoietic stem cell transplantation, characterised by a broad disease spectrum that can affect virtually any organ. Although pulmonary cGvHD is a less common manifestation, it is of great concern due to its severity and poor prognosis. Optimal management of patients with pulmonary cGvHD is complicated and no standardised approach is available.The purpose of this joint European Respiratory Society and European Society for Blood and Marrow ...
Source: Respiratory Care - March 14, 2024 Category: Respiratory Medicine Authors: Saskia Bos John Murray Monia Marchetti Guang-Shing Cheng Anne Bergeron Daniel Wolff Clare Sander Akshay Sharma Sherif M Badawy Zinaida Peric Agnieszka Piekarska Joseph Pidala Kavita Raj Olaf Penack Samar Kulkarni Molly Beestrum Andrea Linke Matthew Rutter Source Type: research
Comparing Budesonide and Fluticasone Propionate in Children with Moderate to Severe Asthma: A Pilot Randomized Controlled Trial
This study aimed to compare the effects of fluticasone propionate (FP) and budesonide (Bud) on the clinical symptoms and control of asthma in children with moderate to severe asthma. In this open-label study, children with moderate to severe asthma were randomly selected to receive either FP 250 mcg or Bud 400 mcg for 3 months. Asthma control test scores were measured in both groups monthly. The clinical symptoms, drug adherence, and rescue medication were also evaluated. A total of 50 patients with ages between 4 and 7 years old were included in the study (25 cases received Bud and 25 cases received FP). Asthma control te...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 13, 2024 Category: Allergy & Immunology Authors: Mansour Sadeghzadeh Parisa Khoshnevisasl Akefeh Ahmadiafshar Nima Motamed Azadeh Pourmarjani Source Type: research
Comparing Budesonide and Fluticasone Propionate in Children with Moderate to Severe Asthma: A Pilot Randomized Controlled Trial
This study aimed to compare the effects of fluticasone propionate (FP) and budesonide (Bud) on the clinical symptoms and control of asthma in children with moderate to severe asthma. In this open-label study, children with moderate to severe asthma were randomly selected to receive either FP 250 mcg or Bud 400 mcg for 3 months. Asthma control test scores were measured in both groups monthly. The clinical symptoms, drug adherence, and rescue medication were also evaluated. A total of 50 patients with ages between 4 and 7 years old were included in the study (25 cases received Bud and 25 cases received FP). Asthma control te...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 13, 2024 Category: Allergy & Immunology Authors: Mansour Sadeghzadeh Parisa Khoshnevisasl Akefeh Ahmadiafshar Nima Motamed Azadeh Pourmarjani Source Type: research
Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale ® system: A first evaluation in humans
CONCLUSIONS: When one inhaler dose was administered via the PI system, the absorbed dose, expressed as AUC24, was approximately twice as high and the CV was less than half, compared to direct inhalation from the same pMDI. Bolus breath hold targeting of drugs from the same aerosol mixture to the peripheral lung and the central airways showed a difference in their appearance in the systemic circulation. Normalized to the same deposited dose, SMX had a 57% higher Cmax in the peripheral lung compared to the central airways. However, from 6 to 24 h after dosing the systemic concentrations of SMX from both regions were quite si...
Source: European Journal of Pharmaceutical Sciences - March 9, 2024 Category: Drugs & Pharmacology Authors: Per Gerde Carl-Olof Sj öberg Helen B äckroos Joakim Englund Marit Wangheim Helena Litorp Source Type: research
Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale ® system: A first evaluation in humans
CONCLUSIONS: When one inhaler dose was administered via the PI system, the absorbed dose, expressed as AUC24, was approximately twice as high and the CV was less than half, compared to direct inhalation from the same pMDI. Bolus breath hold targeting of drugs from the same aerosol mixture to the peripheral lung and the central airways showed a difference in their appearance in the systemic circulation. Normalized to the same deposited dose, SMX had a 57% higher Cmax in the peripheral lung compared to the central airways. However, from 6 to 24 h after dosing the systemic concentrations of SMX from both regions were quite si...
Source: European Journal of Pharmaceutical Sciences - March 9, 2024 Category: Drugs & Pharmacology Authors: Per Gerde Carl-Olof Sj öberg Helen B äckroos Joakim Englund Marit Wangheim Helena Litorp Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
